zurück Home

ZNS - Lymphome: Ergebnisse

allgemeines

RTOG 0227

 Phase I/II Study of Preirradiation Chemotherapy with Methotrexate, Rituximab, and Temozolomid and Postirradiation Temozolomid for Primary Central Vervous System Lymphoma.

RTOG 9310 (1)

 Vor der Strahlentherapie MTX intrathekal und i.v., Procarbazin, Vinchristin.

Juergens 2010

 65 Patienten, systemische und intraventrikuläre Chemotherapie. Hochdosis MTX und Ara-C. Gute Ergebnisse ohne Radiotherapie.

G-PCNSL-SG-1

 Bestrahlung des Ganzhirns nach hoch dosierter Chemotherapie kein Vorteil.

EORTC 20962

 High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy

CALGB 50202

Quellen

 1.) DeAngelis LM, et al.:
Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10.
J Clin Oncol 20(2002):4643-4648

2.) Poortmans PM, et al.:
High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962.
J Clin Oncol 21(2003):4483-4488

3.) Glass J, et al.:
Phase I/II Study of Preirradiation Chemotherapy with Methotrexate, Rituximab, and Temozolomid and Postirradiation Temozolomid for Primary Central Nervous System Lymphoma.
Neuro-Oncology 2006;8:443, Abst. TA-21

 


Impressum                         Zuletzt geändert am 01.03.2016 18:15